BioCentury | Mar 23, 2017
Finance

Biology on the mind

...targets that are genetically linked to dementia. Other companies targeting microglia to treat neurodegeneration include Cardeus Pharmaceuticals Inc....
...Inc. , blocks microglial activation and was previously tested by Astellas to treat pain, but Cardeus...
...Pharma Inc. (Tokyo:4503), Tokyo, Japan Autifony Therapeutics Ltd. London, U.K. Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Cardeus Pharmaceuticals Inc....
BioCentury | Sep 16, 2013
Emerging Company Profile

Cardeus: Microglia blockade

...Astellas Pharma Inc. spinout Cardeus Pharmaceuticals Inc. 's COX-1 inhibitor tamps down neuroinflammation in the brain and could...
...and increased levels of thromboxane A2/prostaglandin H2 (TXA2/PGH2), which are both associated with impaired cognition. Cardeus...
...syndrome (ACS). Cardeus plans to out-license these programs. Astellas does not have a stake in Cardeus...
BioCentury | Apr 4, 2011
Company News

Cardeus, Astellas deal

...Investment. Astellas Venture also plans to invest in the newco. Further terms were not disclosed. Cardeus Pharmaceuticals Inc....
...Menlo Park, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Pharmaceuticals Astellas granted newco Cardeus...
...undisclosed ion channel protein inhibitor; ASP6537, a selective cyclooxygenase-1 (COX-1) inhibitor; and a preclinical compound. Cardeus...
BioCentury | Apr 1, 2011
Company News

Newco Cardeus in-licenses Astellas compounds

...Astellas Pharma Inc. (Tokyo:4503) granted new company Cardeus Pharmaceuticals Inc. (Menlo Park, Calif.) exclusive, worldwide rights, excluding Japan...
...undisclosed ion channel protein inhibitor; ASP6537, a selective cyclooxygenase-1 (COX-1) inhibitor; and a preclinical compound. Cardeus...
...of first negotiation for Europe and the U.S. and right to first refusal in China. Cardeus...
Items per page:
1 - 4 of 4
BioCentury | Mar 23, 2017
Finance

Biology on the mind

...targets that are genetically linked to dementia. Other companies targeting microglia to treat neurodegeneration include Cardeus Pharmaceuticals Inc....
...Inc. , blocks microglial activation and was previously tested by Astellas to treat pain, but Cardeus...
...Pharma Inc. (Tokyo:4503), Tokyo, Japan Autifony Therapeutics Ltd. London, U.K. Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Cardeus Pharmaceuticals Inc....
BioCentury | Sep 16, 2013
Emerging Company Profile

Cardeus: Microglia blockade

...Astellas Pharma Inc. spinout Cardeus Pharmaceuticals Inc. 's COX-1 inhibitor tamps down neuroinflammation in the brain and could...
...and increased levels of thromboxane A2/prostaglandin H2 (TXA2/PGH2), which are both associated with impaired cognition. Cardeus...
...syndrome (ACS). Cardeus plans to out-license these programs. Astellas does not have a stake in Cardeus...
BioCentury | Apr 4, 2011
Company News

Cardeus, Astellas deal

...Investment. Astellas Venture also plans to invest in the newco. Further terms were not disclosed. Cardeus Pharmaceuticals Inc....
...Menlo Park, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Pharmaceuticals Astellas granted newco Cardeus...
...undisclosed ion channel protein inhibitor; ASP6537, a selective cyclooxygenase-1 (COX-1) inhibitor; and a preclinical compound. Cardeus...
BioCentury | Apr 1, 2011
Company News

Newco Cardeus in-licenses Astellas compounds

...Astellas Pharma Inc. (Tokyo:4503) granted new company Cardeus Pharmaceuticals Inc. (Menlo Park, Calif.) exclusive, worldwide rights, excluding Japan...
...undisclosed ion channel protein inhibitor; ASP6537, a selective cyclooxygenase-1 (COX-1) inhibitor; and a preclinical compound. Cardeus...
...of first negotiation for Europe and the U.S. and right to first refusal in China. Cardeus...
Items per page:
1 - 4 of 4